Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions

2014 ◽  
Vol 44 (5) ◽  
pp. 442-449 ◽  
Author(s):  
J. C. Kuo ◽  
C. Hawkins ◽  
D. Yip
Keyword(s):  
Monoclonal Antibodies ◽  
Treatment Outcomes ◽  
Chemotherapeutic Agents ◽  
Hypersensitivity Reactions

scholarly journals The Promise of Integrins as Effective Targets for Anticancer Agents

2002 ◽  
Vol 2 (3) ◽  
pp. 124-130 ◽  
Author(s):  
William L. Rust ◽  
Stephen W. Carper ◽  
George E. Plopper
Keyword(s):  
Monoclonal Antibodies ◽  
Drug Design ◽  
Cell Surface ◽  
Signaling Pathways ◽  
Anticancer Agents ◽  
Chemotherapeutic Agents ◽  
Migration And Invasion ◽  
Chemotherapeutic Drug ◽  
Cellular Processes ◽  
Adenovirus Vectors

This review will briefly describe integrin function, address why integrins are attractive targets for chemotherapeutic drug design, and discuss some ongoing studies aimed at inhibiting integrin activity. Integrins are cell surface heterodimeric receptors. They modulate many cellular processes including: growth, death (apoptosis), adhesion, migration, and invasion by activating several signaling pathways. Many potential chemotherapeutic agents target integrins directly (eg, polypeptides, monoclonal antibodies, adenovirus vectors). These agents may be clinically useful in controlling the metastatic spread of cancer.

scholarly journals Successful olaparib desensitization using a novel one-day protocol

2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Rongbo Zhu ◽  
Stephen Welch ◽  
Hannah Roberts
Keyword(s):  
Adverse Reactions ◽  
Chemotherapeutic Agents ◽  
Hypersensitivity Reactions ◽  
Immediate Hypersensitivity ◽  
Case Presentation ◽  
Tablet Form ◽  
Desensitization Protocol ◽  
Ige Mediated ◽  
Loss Of Tolerance

Abstract Background Olaparib is a revolutionary treatment for patients with ovarian and breast cancer. Currently, there is no established 1-day drug desensitization protocol for patients with olaparib type-1 hypersensitivity reactions despite well documented IgE-mediated adverse reactions occurring with olaparib. Case presentation We report a 58-year-old female with immediate, reproducible IgE-mediated adverse reactions to olaparib tablets with implementation of a 1-day novel desensitization protocol to olaparib. Following desensitization, the patient was successfully transitioned from olaparib capsules to tablets with no loss of tolerance. Conclusions To our knowledge, this is the first reported case of successful olaparib desensitization using a novel 1-day desensitization protocol, and will contribute to drug allergy knowledge, in an area where robust data is lacking. This case demonstrates the important role for drug desensitization in patients with immediate hypersensitivity reactions to chemotherapeutic agents. Furthermore, as olaparib capsules are being phased out in favour of olaparib tablets, we provide a clear case that transitioning from capsule to tablet form did not cause a loss of tolerance.

scholarly journals Biomarkers Associated with Hypersensitivity Reactions to Chemotherapeutic Agents.

2020 ◽  
Vol 145 (2) ◽  
pp. AB100
Author(s):  
F. Javier Fernandez ◽  
Teodorikez Jimenez Rodriguez ◽  
Maria Ruano-Zaragoza ◽  
Purificación Gonzalez-Delgado ◽  
Victor Soriano-Gomis
Keyword(s):  
Chemotherapeutic Agents ◽  
Hypersensitivity Reactions

scholarly journals Hypersensitivity Reactions to Monoclonal Antibodies in Children

Medicina ◽  
2020 ◽  
Vol 56 (5) ◽  
pp. 232
Author(s):  
Francesca Mori ◽  
Francesca Saretta ◽  
Annamaria Bianchi ◽  
Giuseppe Crisafulli ◽  
Silvia Caimmi ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Therapeutic Option ◽  
Provocation Test ◽  
Type I ◽  
Hypersensitivity Reactions ◽  
Biologic Drugs ◽  
Type Iv ◽  
Drug Provocation Test

Biologic drugs are widely used in pediatric medicine. Monoclonal antibodies (mAbs) in particular are a therapeutic option for rheumatic, autoinflammatory and oncologic diseases. Adverse drug reactions and hypersensitivity reactions (HSR) to mAbs may occur in children. Clinical presentation of HSRs to mAbs can be classified according to phenotypes in infusion-related reactions, cytokine release syndrome, both alpha type reactions and type I (IgE/non-IgE), type III, and type IV reactions, all beta-type reactions. The aim of this review is to focus on HSRs associated with the most frequent mAbs in childhood, with particular attention to beta-type reactions. When a reaction to mAbs is suspected a diagnostic work-up including in-vivo and in-vitro testing should be performed. A drug provocation test is recommended only when no alternative drugs are available. In selected patients with immediate IgE-mediated drug allergy a desensitization protocol is indicated. Despite the heavy use of mAbs in childhood, studies evaluating the reliability of diagnostic test are lacking. Although desensitization may be effective in reducing the risk of reactions in children, standardized pediatric protocols are still not available.

Immediate reaction to ibrutinib amenable to oral desensitization

2021 ◽  
pp. 107815522110046
Author(s):  
Neelam A Phadke ◽  
Samantha O Luk ◽  
Ephraim P Hochberg ◽  
Aleena Banerji
Keyword(s):  
Maculopapular Rash ◽  
Chemotherapeutic Agents ◽  
Lymphocytic Leukemia ◽  
Hypersensitivity Reactions ◽  
First Line ◽  
Management Guidelines ◽  
Cutaneous Hypersensitivity ◽  
Ige Mediated ◽  
To Receive ◽  
Oral Desensitization

Introduction Although up to half of patients receiving chemotherapeutic agents develop hypersensitivity reactions to the same, desensitization protocols can induce temporary tolerance to allow patients to continue to receive first-line treatment. Approximately 25% of patients develop cutaneous hypersensitivity reactions to ibrutinib, but there are no published management guidelines. Case report We describe the case of a 71-year-old woman with chronic lymphocytic leukemia who developed a delayed maculopapular rash with lip tingling and swelling following ibrutinib therapy. Management and outcome We performed a novel 11-step desensitization procedure to ibrutinib allowing us to successfully induce tolerance against IgE-mediated symptoms in this patient. Discussion As indications for ibrutinib use expand and more patients present with IgE-mediated symptoms, we expect that this protocol will provide benefit for many such patients.

Sign in / Sign up

Export Citation Format

Share Document